公开(公告)号：US20220241329A1

公开(公告)日：2022-08-04

申请号：US17592105

申请日：2022-02-03

Applicant: Allogene Therapeutics, Inc.

Inventor： Muneeswara Babu MEDI ,  Zhuojin XU ,  Jung S. LEE ,  Yajin NI ,  Mark W. LEONARD

IPC: A61K35/17 ,  A01N1/02 ,  C12N5/0783

Abstract: Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.

公开(公告)号：US20220033462A1

公开(公告)日：2022-02-03

申请号：US17385805

申请日：2021-07-26

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： ARVIND RAJPAL ,  Shobha Chowdary Potluri ,  Laurent Poirot ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Donna Marie Stone ,  Barbra Johnson Sasu

IPC: C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.

公开(公告)号：US20210107979A1

公开(公告)日：2021-04-15

申请号：US16802822

申请日：2020-02-27

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Yi ZHANG ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Silvia K. TACHEVA-GRIGOROVA ,  Barbra Johnson SASU

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/00

Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.

公开(公告)号：US20210106498A1

公开(公告)日：2021-04-15

申请号：US17064241

申请日：2020-10-06

Applicant: Allogene Therapeutics, Inc.

Inventor： Stephen Flores ,  Patricia M. Kessler

IPC: A61J1/16 ,  A61J1/14 ,  B65D23/00 ,  B65D23/08

Abstract: A vial jacket configured to receive a label. The vial jacket includes a plastic material having a cryogenic operating temperature range, a hinge formed in the plastic material, a locking mechanism, and an opening formed in the plastic material. The plastic material is dimensioned to surround at least a portion of a vial. The hinge defines a first half shell having a first edge and a second half shell having a second edge. The locking mechanism is configured to secure the first edge of the first half shell to the second edge of the second half shell. The opening has an axial length and a transverse length.

公开(公告)号：US20250051421A1

公开(公告)日：2025-02-13

申请号：US18741447

申请日：2024-06-12

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui LIN ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Barbra Johnson SASU

IPC: C07K14/715 ,  A61K39/00 ,  A61P35/00 ,  C07K16/40 ,  C12N5/0783 ,  C12N7/00 ,  C12N15/86

Abstract: Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.

公开(公告)号：US12104188B2

公开(公告)日：2024-10-01

申请号：US17716253

申请日：2022-04-08

Applicant: Allogene Therapeutics, Inc.

Inventor： Meritxell Galindo Casas ,  Thomas John Van Blarcom

IPC: C12N9/64 ,  A61K31/7088 ,  A61K35/17 ,  A61K38/48 ,  A61K38/52 ,  C12N5/0783 ,  C12N9/90 ,  C12N11/18

CPC classification number: C12N9/6472 ,  A61K31/7088 ,  A61K35/17 ,  A61K38/4873 ,  A61K38/52 ,  C12N5/0636 ,  C12N9/90 ,  C12N11/18 ,  C12Y304/22062 ,  C12Y502/01008 ,  C07K2319/50 ,  C07K2319/70 ,  C12N2501/734 ,  C12N2510/00 ,  C12N2740/16043

Abstract: Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides. The disclosure further provides polynucleotides encoding these proteins, engineered host cells containing these polynucleotides and proteins, including host cells that co-express a chimeric antigen receptor, and methods of making and using the same.

公开(公告)号：US20240277763A1

公开(公告)日：2024-08-22

申请号：US18395996

申请日：2023-12-26

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Thomas Charles PERTEL ,  Barbra Johnson SASU ,  Mark W. LEONARD

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70596 ,  C07K16/2803 ,  C12N5/0636 ,  A61K2039/505 ,  C07K2317/76 ,  C07K2319/33 ,  C12N2510/00 ,  C12N2740/15043

Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically birnds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.

公开(公告)号：US20240216430A1

公开(公告)日：2024-07-04

申请号：US18521196

申请日：2023-11-28

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Zhe LI ,  Siler PANOWSKI ,  Barbra Johnson SASU ,  Bryan A. SMITH ,  Thomas John VAN BLARCOM ,  Tao SAI ,  Guoyun ZHU

IPC: A61K35/17 ,  A61K39/00 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464438 ,  C07K16/2875 ,  A61K2039/505 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/23 ,  A61K2239/29 ,  A61K2239/31 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are Claudin 18.2 binding agents and chimeric antigen receptors (CARs) comprising a Claudin 18.2 binding molecule that specifically binds to Claudin 18.2; and immune cells comprising these Claudin 18.2-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using Claudin 18.2-specific CARs and Claudin 18.2 binding agents, and immune cells comprising Claudin 18.2-specific CARs.

公开(公告)号：US20240101710A1

公开(公告)日：2024-03-28

申请号：US18468854

申请日：2023-09-18

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Zea Melton ,  Tao Sai ,  Thomas John Van Blarcom

IPC: C07K16/42 ,  A61K49/00 ,  C07K1/22 ,  C07K16/28 ,  C12N5/0783 ,  G01N33/569

CPC classification number: C07K16/4266 ,  A61K49/0058 ,  C07K1/22 ,  C07K16/2878 ,  C12N5/0636 ,  G01N33/56972 ,  C07K2317/622 ,  C12N2501/998

Abstract: Provided herein are anti-idiotype antibodies that specifically recognize anti-BCMA antibody moieties, in particular, anti-BCMA antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of anti-idiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-BCMA CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.

公开(公告)号：US20230407252A1

公开(公告)日：2023-12-21

申请号：US18308797

申请日：2023-04-28

Applicant: Allogene Therapeutics, Inc.

Inventor： Meng-Yin LIN ,  Hayung YOON ,  Thomas Charles PERTEL ,  Barbra Johnson SASU

IPC: C12N5/0783 ,  C07K14/725

CPC classification number: C12N5/0636 ,  C07K14/7051 ,  C12N2510/00 ,  C07K2319/03 ,  C07K2319/02

Abstract: Provided herein are methods, kits and reagents for analyzing the attributes of cell populations, such as donor cells prior to modification to provide engineered cells, e.g., engineered immune cells, such as CAR T cells. For example, provided herein are methods of determining the amount or percentage of biomarkers and/or secretion profiles of donor cell populations, selecting donor cells with certain biomarkers and/or secretion profiles, and engineering the CAR T cells from the selected donor cells.